Statistical Considerations in Design Space Development (Part III of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 Pharmaceutical Technology All results
Statistical Considerations in Design Space Development (Part III of III)
In the final article of a three-part series, the authors discuss how to present a design space and evaluate its graphical representation.
 Sep 2, 2010 Pharmaceutical Technology Volume 34, Issue 9, pp. 52-61
 Q27: Where should the NOR be inside the design space? How close can the NOR be to the edge of design space? A: Once the design space is established, there is often a desire to map out the area where one would operate routinely. Typically, NOR is based on target settings considering variability in process parameters. The target settings could be based on the optimality of quality, yield, throughput, cycle-time, cost, and so forth. The NOR around this target could be based as a function of equipment and control-systems variability. However, how close the NOR can be from the edge of the design space depends on how the design space is developed. For example: If the design space is constructed based on the predicted values, then historically, the normal operating range is developed as a small interval around a set point. This NOR can move throughout the design space, but should include a buffer to keep the NOR from the edge and allow the NOR to be sufficiently within the design space. The sources of variability to consider in developing the buffer between the NOR and the design space edge are: variability associated with inputs such as raw/starting materials; variability in process controls, including set point tolerances and set point drifts; any operator-to-operator variability; measurement error (whether these are at-line or off-line); and any error associated with the modeling of the surface (e.g., amount of data, the factors and levels chosen, scale-up uncertainty). If the design space description includes an interval-based approach which points to an area of higher assurance then, data dependent, there may be no buffer between the NOR and the interval boundary. The interval boundary may need to be updated as more manufacturing data become available. The design space boundary may stay constant. In any case, every company should have sound quality systems in place to ensure appropriate oversight on any changes to NORs. Q28: I didn't run experiments along my design space boundary. How do I demonstrate that the boundary is acceptable? A: The design space will only be as good as the mathematical or scientific models used to develop the design space. These models can be used to produce predictions with uncertainty bands at points of interest along the edge of the design space, which is contained within the experimental region. If these values are well within the specifications and there is significant process understanding in the models, then the prediction may be sufficient. Q29: If I use production-size batches to confirm my design space, how should I choose the number of batches to run, and what strategy should I apply to select the best points? A: There is no single recipe to choose the points to run in order to verify the design space when developed subscale. Several options are provided in the answer to Question 17 (see Part II of this article series (2)). Briefly, using either mechanistic or empirical models along with performing replicates could provide some idea of the average response along with an estimate of the magnitude of the variability. Alternatively, using existing models and running a few points at the most extreme predicted values may be a reasonable approach if the design space truly provides assurance that the critical quality attribute requirements will be met. Finally, a highly fractionated factorial (supersaturated) experiment of production size batches matched to the subscale batches is another way to confirm the design space.

| Weekly
| Monthly
|Monthly
| Weekly
 Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease. 23%
Oversee medical treatment of patients in the US. 14%
Provide treatment for patients globally. 7%
All of the above. 47%
No government involvement in patient treatment or drug development. 9%
Most Viewed Articles
 Columnists Outsourcing Outlook Jim MillerOutside Looking In sponsored by Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis Regulatory Watch Jill Wechsler New Era for Generic Drugs European Regulatory WatchSean MilmoTackling Drug Shortages